Investors Target GeneDx Holdings in Securities Fraud Class Action

The complaint centers on allegations that GeneDx violated the Securities Exchange Act of 1934 by issuing false and misleading statements to investors. The core of the dispute emerged following the company’s first-quarter 2026 financial report released on May 4. During that disclosure, GeneDx reported a significant decline in adjusted gross margins, downward revisions to projected earnings, and a $31.3 million impairment charge linked to Fabric Genomics.

Legal counsel Brian Schall argues these disclosures revealed that the company’s earlier public statements failed to accurately represent its financial standing during the class period. Investors who suffered losses as a result of these developments are encouraged to contact the firm to discuss potential participation in the suit. Currently, the class remains uncertified, meaning shareholders who choose not to take action will remain absent class members without formal legal representation.